Artificial Intelligence in Drug Design

被引:172
|
作者
Hessler, Gerhard [1 ]
Baringhaus, Karl-Heinz [2 ]
机构
[1] R&D, Integrated Drug Discovery, Ind Pk Hoechst, D-65926 Frankfurt, Germany
[2] R&D, Ind Pk Hoechst, D-65926 Frankfurt, Germany
来源
MOLECULES | 2018年 / 23卷 / 10期
关键词
artificial intelligence; deep learning; neural networks; property prediction; quantitative structure-activity relationship (QSAR); quantitative structure-property prediction (QSPR); de novo design; MACHINE LEARNING-METHODS; DEEP NEURAL-NETWORKS; MOLECULAR DESCRIPTORS; PREDICTION; DISCOVERY; CHEMOINFORMATICS; ARCHITECTURES; FINGERPRINTS; CHEMISTRY; SYSTEM;
D O I
10.3390/molecules23102520
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Artificial Intelligence (AI) plays a pivotal role in drug discovery. In particular artificial neural networks such as deep neural networks or recurrent networks drive this area. Numerous applications in property or activity predictions like physicochemical and ADMET properties have recently appeared and underpin the strength of this technology in quantitative structure-property relationships (QSPR) or quantitative structure-activity relationships (QSAR). Artificial intelligence in de novo design drives the generation of meaningful new biologically active molecules towards desired properties. Several examples establish the strength of artificial intelligence in this field. Combination with synthesis planning and ease of synthesis is feasible and more and more automated drug discovery by computers is expected in the near future.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Artificial intelligence in drug design
    Feisheng Zhong
    Jing Xing
    Xutong Li
    Xiaohong Liu
    Zunyun Fu
    Zhaoping Xiong
    Dong Lu
    Xiaolong Wu
    Jihui Zhao
    Xiaoqin Tan
    Fei Li
    Xiaomin Luo
    Zhaojun Li
    Kaixian Chen
    Mingyue Zheng
    Hualiang Jiang
    [J]. Science China(Life Sciences)., 2018, 61 (10) - 1204
  • [2] Artificial intelligence in drug design
    Feisheng Zhong
    Jing Xing
    Xutong Li
    Xiaohong Liu
    Zunyun Fu
    Zhaoping Xiong
    Dong Lu
    Xiaolong Wu
    Jihui Zhao
    Xiaoqin Tan
    Fei Li
    Xiaomin Luo
    Zhaojun Li
    Kaixian Chen
    Mingyue Zheng
    Hualiang Jiang
    [J]. Science China Life Sciences, 2018, (10) : 1191 - 1204
  • [3] Artificial intelligence for drug design
    Aris Persidis
    Andreas Persidis
    [J]. Nature Biotechnology, 1997, 15 : 1035 - 1036
  • [4] Artificial intelligence for drug design
    Persidis, A
    Persidis, A
    [J]. NATURE BIOTECHNOLOGY, 1997, 15 (10) : 1035 - 1036
  • [5] Artificial intelligence in drug design
    Zhong, Feisheng
    Xing, Jing
    Li, Xutong
    Liu, Xiaohong
    Fu, Zunyun
    Xiong, Zhaoping
    Lu, Dong
    Wu, Xiaolong
    Zhao, Jihui
    Tan, Xiaoqin
    Li, Fei
    Luo, Xiaomin
    Li, Zhaojun
    Chen, Kaixian
    Zheng, Mingyue
    Jiang, Hualiang
    [J]. SCIENCE CHINA-LIFE SCIENCES, 2018, 61 (10) : 1191 - 1204
  • [6] Artificial intelligence in drug design
    Feisheng Zhong
    Jing Xing
    Xutong Li
    Xiaohong Liu
    Zunyun Fu
    Zhaoping Xiong
    Dong Lu
    Xiaolong Wu
    Jihui Zhao
    Xiaoqin Tan
    Fei Li
    Xiaomin Luo
    Zhaojun Li
    Kaixian Chen
    Mingyue Zheng
    Hualiang Jiang
    [J]. Science China Life Sciences, 2018, 61 : 1191 - 1204
  • [7] Artificial Intelligence in drug design
    Baringhaus, Karl-Heinz
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [8] Artificial intelligence in chemistry and drug design
    Nathan Brown
    Peter Ertl
    Richard Lewis
    Torsten Luksch
    Daniel Reker
    Nadine Schneider
    [J]. Journal of Computer-Aided Molecular Design, 2020, 34 : 709 - 715
  • [9] Artificial intelligence in chemistry and drug design
    Brown, Nathan
    Ertl, Peter
    Lewis, Richard
    Luksch, Torsten
    Reker, Daniel
    Schneider, Nadine
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2020, 34 (07) : 709 - 715
  • [10] Rethinking drug design in the artificial intelligence era
    Petra Schneider
    W. Patrick Walters
    Alleyn T. Plowright
    Norman Sieroka
    Jennifer Listgarten
    Robert A. Goodnow
    Jasmin Fisher
    Johanna M. Jansen
    José S. Duca
    Thomas S. Rush
    Matthias Zentgraf
    John Edward Hill
    Elizabeth Krutoholow
    Matthias Kohler
    Jeff Blaney
    Kimito Funatsu
    Chris Luebkemann
    Gisbert Schneider
    [J]. Nature Reviews Drug Discovery, 2020, 19 : 353 - 364